Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Summary

Polyplus-transfection® SA, a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics, today announces the launch of jetOPTIMUS®, a new reagent for powerful nanoparticle DNA transfection.

“As cell and gene therapies become more advanced and complex, this increases the need to address DNA transfection of very challenging cells. To increase efficiency in hard-to-transfect cells, scientists have to use ever-more advanced reagents,” said Patrick Erbacher, CSO, Polyplus-transfection. “We recognized the need to combine the efficiency, safety and morphology requirements of mammalian cell transfection. To date, the market has not supplied what is expected today to fulfil all needs. Polyplus-transfection believes jetOPTIMUS will equip academics in the most advanced cell and gene therapy based research with the best solution.”

The reagent has been designed to be primarily used for research purposes across academic research in mammalian cells, especially hard-to-transfect cells. The reagent will result in the most efficient mammalian cell transfection product on the market, maximizing gene expression. This ensures improved cell viability and morphology after transfection for more relevant data. The requirement of a minimal reagent volume and DNA quantity will considerably increase costefficiency. The cost per reaction will be decreased by up to seven times when compared to other market leading products.

The reagent is the latest product in the Polyplus-transfection portfolio of reagents for the transfection of genes, oligonucleotides and siRNA. jetOPTIMUS has been designed to be the best-in-class DNA transfection reagent for everyday transfection experiments. It will provide solutions for those working with all types of cells and transfection applications. It solves a range of issues encountered across the market with hard to transfect cells.

About Polyplus-transfection

Polyplus-transfection SA is a biotechnology company specializing in delivery solutions and a market leader for transfection reagents for cell & gene therapy. Polyplus-transfection’s vast portfolio of delivery solutions can be used for all types  of applications, from research and process development, all the way to clinical trials. Located close to the University of Strasbourg in Eastern France, Polyplustransfection has been ISO 9001-certified since 2002.

Press Contact
Polyplus-transfection SA
Géraldine Guérin-Peyrou
phone: +33 (0)3 90406186
e-mail: ggp@polyplus-transfection.com